Belite Bio Management
Management criteria checks 2/4
Belite Bio's CEO is Tom Lin, appointed in Nov 2021, has a tenure of 3.17 years. directly owns 1.72% of the company’s shares, worth $33.01M. The average tenure of the management team and the board of directors is 3.2 years and 3.2 years respectively.
Key information
Tom Lin
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 3.2yrs |
| CEO ownership | 1.7% |
| Management average tenure | 3.2yrs |
| Board average tenure | 3.2yrs |
Recent management updates
Recent updates
We're Interested To See How Belite Bio (NASDAQ:BLTE) Uses Its Cash Hoard To Grow
Sep 26
Are Investors Undervaluing Belite Bio, Inc (NASDAQ:BLTE) By 45%?
Jul 03We're Hopeful That Belite Bio (NASDAQ:BLTE) Will Use Its Cash Wisely
Mar 20An Intrinsic Calculation For Belite Bio, Inc (NASDAQ:BLTE) Suggests It's 49% Undervalued
Jan 10Belite Bio, Inc's (NASDAQ:BLTE) Intrinsic Value Is Potentially 25% Below Its Share Price
Jul 31We're Not Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn
May 03Belite Bio down 21% after disappointing mid-stage results of rare eye disease candidate
Oct 03Belite Bio receives approval of begin LBS-008 phase 3 trial in China
Sep 16Belite Bio adds 15% as pivotal trial for lead asset starts in U.S.
Aug 22Belite Bio GAAP EPS of -$0.23 beats by $0.05
Aug 12Belite Bio (NASDAQ:BLTE) Is In A Good Position To Deliver On Growth Plans
Aug 01Belite seeks FDA nod to proceed with phase 3 trial of genetic eye disease treatment
Jul 19CEO
Tom Lin (46 yo)
3.2yrs
Tenure
Dr. Yu-Hsin Lin, also known as Tom, MBA MMed PhD (Med) is the founder and has served as Director of Belite Bio Inc since March 2018 and its Chairman and served as the Chief Executive Officer since November...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board of Directors & CEO | 3.2yrs | no data | 1.72% $ 33.0m | |
| CFO & Director | 4.8yrs | no data | 1.01% $ 19.4m | |
| Chief Scientific Officer | 3.2yrs | no data | no data | |
| Chief Medical Officer & Member of Ophthalmology Clinical Advisory Board | less than a year | no data | no data |
3.2yrs
Average Tenure
46yo
Average Age
Experienced Management: BLTE's management team is considered experienced (3.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board of Directors & CEO | 6.8yrs | no data | 1.72% $ 33.0m | |
| CFO & Director | 3.2yrs | no data | 1.01% $ 19.4m | |
| Chief Medical Officer & Member of Ophthalmology Clinical Advisory Board | no data | no data | no data | |
| Member of Ophthalmology Clinical Advisory Board | no data | no data | no data | |
| Independent Director | 2.8yrs | no data | no data | |
| Member of Ophthalmology Clinical Advisory Board | no data | no data | no data | |
| Member of Ophthalmology Clinical Advisory Board | no data | no data | no data | |
| Director | 3.2yrs | no data | no data | |
| Director | 3.2yrs | no data | no data | |
| Independent Director | 2.8yrs | no data | no data | |
| Independent Director | 2.8yrs | no data | no data | |
| Member of Ophthalmology Clinical Advisory Board | no data | no data | no data |
3.2yrs
Average Tenure
46yo
Average Age
Experienced Board: BLTE's board of directors are considered experienced (3.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/06 04:33 |
| End of Day Share Price | 2025/01/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Belite Bio, Inc is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bruce Jackson | Benchmark Company |
| Jennifer Kim | Cantor Fitzgerald & Co. |
| Yi Chen | H.C. Wainwright & Co. |